MedTrace Logo

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

NCT02216266 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-03-10

No results posted yet for this study

Summary

Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery

Conditions

  • Suspected Delirium After Elective or Emergency Heart Surgery
  • CAM-ICU Diagnosed Delirium

Interventions

DRUG

Physostigmine

OTHER

Sodium Chloride solution

Sponsors & Collaborators

  • Goethe University

    collaborator OTHER

  • Dr. Franz Köhler Chemie GmbH (study medication and labeling)

    collaborator UNKNOWN

  • PD Dr. Bertram Scheller

    lead OTHER

Principal Investigators

  • Bertram Scheller, MD · Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy of Goethe-University Frankfurt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02216266 on ClinicalTrials.gov